The chemical class termed C3orf43 Inhibitors consists of a collection of compounds strategically selected to modulate signaling pathways associated with the C3orf43 protein. While direct inhibitors for C3orf43 may not be explicitly identified, potential activators and modulators of related pathways can be explored. Metformin, a widely used antidiabetic drug, activates AMP-activated protein kinase (AMPK), which can influence cellular energy homeostasis and potentially affect C3orf43 activity. Forskolin activates adenylate cyclase, leading to increased cAMP levels, a potential modulator of C3orf43 signaling pathways.
AICAR (Acadesine) activates AMPK, contributing to cellular energy homeostasis, providing another avenue for potential modulation of C3orf43. GW501516 (Cardarine) activates PPARδ, influencing metabolic pathways that might intersect with C3orf43 function. Dorsomorphin (Compound C) is an AMPK inhibitor, affecting AMPK-dependent cellular processes, potentially influencing C3orf43 regulation. LY294002 inhibits PI3-kinase, disrupting the PI3K/AKT signaling axis, which can potentially affect C3orf43 signaling. Rapamycin, an mTOR inhibitor, disrupts mTOR-dependent cellular events, providing another potential avenue for modulation. SB216763 is a GSK-3 inhibitor, impacting the Wnt/β-catenin signaling pathway, which could be linked to C3orf43. A-769662, another AMPK activator, can contribute to cellular energy homeostasis, potentially influencing C3orf43 activity. Rosiglitazone activates PPARγ, influencing transcriptional regulation that may intersect with C3orf43. PD98059 selectively inhibits MEK1, disrupting the MAPK pathway, which could be involved in C3orf43 signaling. SB431542 inhibits the TGF-β type I receptor, modulating the TGF-β pathway, providing another potential avenue for C3orf43 modulation. Collectively, these compounds offer a diverse toolkit for investigating the modulation of cellular processes associated with C3orf43, even in the absence of direct inhibitors, by targeting key pathways involved in its regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Activates AMP-activated protein kinase (AMPK) | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
Activates AMPK, influencing cellular energy homeostasis | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $80.00 $175.00 | 28 | |
Activates PPARδ, influencing metabolic pathways | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $182.00 $736.00 | 28 | |
AMPK inhibitor, affecting AMPK-dependent cellular processes | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3-kinase, disrupting the PI3K/AKT signaling | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, disrupting mTOR-dependent cellular events | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
GSK-3 inhibitor, impacting Wnt/β-catenin signaling | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
Activates AMPK, contributing to cellular energy homeostasis | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Activates PPARγ, impacting transcriptional regulation | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Selective inhibitor of MEK1, disrupting MAPK pathway | ||||||